Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders
NCT00511537 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2013-08-02
Summary
This study performs HLA matched stem cell transplantation from unrelated donors in adults who require stem cell transplantation but do not have a matched related donor available. The incidence of graft-versus-host disease in unrelated stem cell transplantation is recorded. This study also monitors the activity and toxicity of total body irradiation and cyclosphosphamide followed by stem cell transplantation from matched unrelated donors.
Conditions
Sponsors & Collaborators
-
University of California, San Francisco
lead OTHER
Principal Investigators
-
Thomas G. Martin, M.D. · University of California, San Francisco
Eligibility
- Min Age
- 16 Years
- Max Age
- 54 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-01-31
- Primary Completion
- 2009-06-30
- Completion
- 2009-06-30
Countries
- United States
Study Locations
More Related Trials
-
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
NCT00301951 ·Status: COMPLETED ·Phase: PHASE1
-
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
NCT03615105 ·Status: TERMINATED ·Phase: PHASE2
-
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
NCT00054327 ·Status: COMPLETED ·Phase: PHASE2
-
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
NCT03032783 ·Status: COMPLETED ·Phase: PHASE2
-
Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors
NCT00186225 ·Status: COMPLETED ·Phase: NA
-
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
NCT00185523 ·Status: TERMINATED
-
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
NCT00055653 ·Status: COMPLETED ·Phase: PHASE2
-
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
NCT04530487 ·Status: TERMINATED ·Phase: PHASE2
-
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
NCT00053196 ·Status: COMPLETED ·Phase: PHASE2
-
Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma
NCT00003187 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
NCT00107354 ·Status: COMPLETED ·Phase: PHASE1
-
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
NCT00611351 ·Status: COMPLETED ·Phase: PHASE2
-
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders
NCT00186576 ·Status: COMPLETED ·Phase: NA
-
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01028716 ·Status: TERMINATED ·Phase: PHASE2
-
A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia
NCT05757310 ·Status: RECRUITING ·Phase: PHASE1
-
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
NCT00002718 ·Status: COMPLETED ·Phase: PHASE2
-
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
NCT03712878 ·Status: COMPLETED ·Phase: PHASE2
-
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
NCT00080925 ·Status: COMPLETED ·Phase: PHASE1
-
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
NCT00003196 ·Status: COMPLETED ·Phase: NA
-
Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00054353 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
NCT00534118 ·Status: COMPLETED ·Phase: NA
-
Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00003960 ·Status: COMPLETED ·Phase: PHASE2
-
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
NCT00521430 ·Status: COMPLETED ·Phase: NA
-
Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer
NCT00301860 ·Status: TERMINATED ·Phase: NA
-
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
NCT00533923 ·Status: COMPLETED ·Phase: PHASE2